DNTH
NASDAQ
$101
Dianthus Therapeutics Inc (DNTH)
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $128.58 (+27.31%)
Market Cap
$5.45B
Free Cash Flow Yield
-2.39%
Beta (5Y)
1.11
Price Chart
Valuation
Market Cap$5.45B
P/S4088.10
P/B4.61
Profitability
Total Revenue (TTM)$873K
Gross Profit (TTM)$1.34M
EBITDA-$191M
Operating Margin-10050%
EPS-$4.08
Financial Health
Free Cash Flow Yield-2.39%
Growth & Risk
FCF 5Y CAGR+15.13%
Beta (5Y)1.11
Sharpe Ratio2.70